ShannonMaudeMD

PubMed

• 198 citations
  PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
  Vivek Narayan, Julie S Barber-Rotenberg, In-Young Jung, Simon F Lacey, Andrew J Rech
  Nature Medicine. 2022-04-01
• 492 citations
  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
  Shannon L. Maude, David T. Teachey, David L. Porter, Stephan A. Grupp
  Blood. 2015-06-25
• 308 citations
  Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
  Julie C. Fitzgerald, Scott L. Weiss, Shannon L. Maude, David M. Barrett, Simon F. Lacey
  Critical Care Medicine. 2017-02-01

Journal Articles

• Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell  
  Vijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature

Abstracts/Posters

• Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
  Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy
  Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019
  Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes 
  60th American Society of Hematology Annual Meeting - 11/30/2018